Coronavirus: Pfizer vaccine “90% effective”



The Covid-19 vaccine developed by Pfizer and BionTech reduces the risk of infection by 90%, the two laboratories announced today, citing the preliminary results of the third phase of clinical trials, the last step before submitting a marketing authorization. of the vaccine was measured by comparing the number of participants infected with the new coronavirus in the group receiving the vaccine and in the placebo group, “seven days after the second dose” and 28 days after the first, the two companies explain. This means that the vaccine is effective about a month after the first of the two doses required. 90% is well above the 50% threshold set by US regulators for the approval of vaccines. Pfizer vaccine will be one of the first vaccines to be approved by the US Food and Drug Administration (FDA). mRNAs reaching the market, and possibly the first worldwide. No side effectsAccording to the announcement, the Independent Data Monitoring Committee (DMC) which analyzed the preliminary findings “has not reported any serious safety concerns, and recommends that the study be continued. for the collection of additional efficiency and safety data. The data will be communicated to the regulators worldwide. ”Pfizer, which has marketed the vaccine developed by BioNTech, expects production to reach 50 million doses of the vaccine by 2020 and 1.3 billion doses in 2021. “Today is a great day for science and humanity,” said Dr. Albert Burla, President and CEO of Pfizer. “We are reaching this crucial milestone […,] “At a time when people need it most, as coronavirus cases hit a new record, hospitals are nearing full capacity and economies are struggling to reopen.” Phase 3 of the trials has so far enrolled nearly 44,000 volunteers, of whom 39,000 have already received both required doses of the vaccine, which is temporarily named BNT162b2. So far only 94 cases have been reported among the volunteers. The study will continue until 164 confirmed cases are recorded among the participants, who were selected to give a representative picture of the US population. The study examines the effectiveness of the vaccine not only in preventing Covid-19 infection in healthy volunteers, but also in volunteers. SARS-CoV-2 vaccine New technology Vaccine Like all vaccines, Pfizer’s experimental BNT162b2 was designed to trigger the production of antibodies that recognize specific proteins in the virus and target the immune system. vaccines, the Pfizer experimental preparation does not contain parts of the virus itself, or antigens, but mRNA molecules that encode the instructions for producing the antigens. In other words, the candidate vaccine was designed to instruct human cells to synthesize molecular parts of the coronavirus on their own. To date, no mRNA vaccine has been approved for use in humans, although the new technology is already used in some veterinary vaccines. MRNA technology is expected to be widely used in the future, as it significantly speeds up the production process and reduces costs. Follow it on Google News and be the first to know all the news See all the latest News from Greece and the World, at



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *